Collectively, these results clearly demonstrated that metformin and LKB1 inhibited the effect of TGF-β on phosphorylation of Smad2/3, leading to suppression of its transcription activity in breast cancer cells and in precancerous lesion. The gene discussed is SMAD2; the disease is breast carcinoma.